3 weeks Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS GroupMarketBeat
UBS Group raised their price target on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a report on Friday.
XUBS Group raised their price target on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a report on Friday.
X